Spero Therapeutics (SPRO) 10-Q 2022 Q3 Quarterly report

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Spero Therapeutics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended September 30, 2022 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2022	/s/ Ankit Mahadevia, M.D.
	Ankit Mahadevia, M.D.
	President and Chief Executive Officer
	(Principal Executive Officer)

Dated: November 14, 2022	/s/ Satyavrat Shukla
	Satyavrat Shukla
	Chief Financial Officer and Treasurer
	(Principal Financial Officer)